1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Epigenetic Aging: new trials by email Literature Review of Epigenetic Aging trials Research Report on Epigenetic Aging
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART - Epigenetic Aging | Phase 2 | Not yet recruiting | The University of Texas Health Science Center, Houston | 60 | 2026-10-30 | 2026-10-23 |
| Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial TRIIM Treatment, Active Control - Epigenetic Aging, Immunosenescence | Phase 2 | Recruiting | Intervene Immune, Inc. | 85 | 2020-11-23 | 2025-05-07 |
Racivir (1) · Tenofovir (1) · tenofovir alafenamide (1)
Intervene Immune, Inc. (1) · The University of Texas Health Science Center, Houston (1)
United States (2)